Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T18:42:44.677Z.
Calculation as of: 2026-10-06T18:42:44.677Z.
Quote observation: 2026-10-06T18:27:32.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: f7eba9f13d95fb6821c25c67f521ed103bec1ea18c2b869fb2c3b9acf85efa0e
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
Passage Bio, Inc.
Market Cap
$13.11M
EV/EBIT Ratio
N/A
| NAME | MARKET CAP | EV/EBIT RATIO |
|---|---|---|
| Passage Bio, Inc. (PASG) | $13.11M | N/A |
| IN8bio, Inc. (INAB)vs › | $13.11M | N/A |
| Citius Pharmaceuticals, Inc. (CTXR)vs › | $13.23M | N/A |
| Optimi Health Corp. (OPTH)vs › | $13.48M | N/A |
| Cytosorbents Corporation (CTSO)vs › | $12.60M | N/A |
| Tempest Therapeutics, Inc. (TPST)vs › | $12.54M | N/A |
| Bullfrog AI Holdings, Inc. Common Stock (BFRG)vs › | $12.50M | N/A |
| Dare Bioscience, Inc. (DARE)vs › | $12.51M | N/A |
| Cellectar Biosciences, Inc. (CLRB)vs › | $12.46M | N/A |
| Lantern Pharma Inc. (LTRN)vs › | $12.40M | N/A |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
